Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of palliative medicine"
DOI: 10.1089/jpm.2022.0491
Abstract: Management of cancer-associated pain warrants consideration of many factors, including characterization and etiology of the pain, socioeconomic factors, medication tolerance, and substance use history. Kratom (Mitragyna speciosa) is an herbal substance with stimulant and analgesic… read more here.
Keywords: kratom; buprenorphine naloxone; opioid; kratom withdrawal ... See more keywords